Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026

(NASDAQ:GRCE) Grace Therapeutics, Inc. announced its participation in upcoming healthcare industry and investor conferences during November 2026. Chief Executive Officer Prashant Kohli will represent the company at BIO-Europe 2026, a global biopharma partnering event held in Cologne, Germany from November 9-11, 2026. The company will also participate in the Craig-Hallum 17th Annual Alpha Select Conference on Tuesday, November 17, 2026, in New York, NY. Grace Therapeutics is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. The company's lead clinical asset is GTx-104, an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH). GTx-104 is a novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients. GTx-104 has been granted Orphan Drug Designation by the FDA. This designation provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval. GTx-104 also benefits from additional intellectual property protection with 52 granted and pending patents. Registration for the Craig-Hallum conference is by invitation only. Grace Therapeutics’ drug delivery technologies are designed to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. The company’s pipeline and intellectual property estate are focused on rare and life-threatening medical emergencies such as aSAH. The company’s participation in these conferences is aimed at engaging with industry representatives and investors.